.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
McKinsey
Cipla
Chubb
Federal Trade Commission
Deloitte
Daiichi Sankyo
Citi
Colorcon
Mallinckrodt

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Abstract:The invention provides suspensions of micronized fenofibrate. The suspensions can comprise micronized fenofibrate in a solution of hydrophilic polymers. The suspensions can further comprise one or more surfactants.
Inventor(s): Stamm; Andre (Griesheim, FR), Seth; Pawan (Irvine, CA)
Assignee: Laboratoires Fournier, SA (Dijon, FR)
Filing Date:Feb 21, 2002
Application Number:10/078,500
Claims:1. A suspension of micronized fenofibrate having a size less than 20 .mu.m in a solution of at least one hydrophilic polymer; wherein the hydrophilic polymer is present in an amount from 5 to 40% by weight; and wherein the hydrophilic polymer is a polyvinylpyrrolidone, a poly(vinyl alcohol), a hydroxypropylcellulose, a hydroxymethylcellulose, a hydroxypropylmethylcellulose, a gelatin, or a mixture of two or more thereof.

2. The suspension according to claim 1, wherein the fenofibrate has a size less than 10 .mu.m.

3. The suspension according to claim 1, wherein the fenofibrate is present in an amount from 1 to 40% by weight.

4. The suspension according to claim 3, wherein the fenofibrate is present in an amount from 10 to 25% by weight.

5. The suspension according to claim 1, wherein the hydrophilic polymer is present in an amount from 10 to 25% by weight.

6. The suspension according to claim 1, wherein the hydrophilic polymer is a polyvinylpyrrolidone.

7. The suspension according to claim 1, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/10 and 4/1.

8. The suspension according to claim 7, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/2 and 2/1.

9. The suspension according to claim 1, further comprising at least one surfactant.

10. The suspension according to claim 9, wherein the surfactant is present in an amount up to 10% by weight.

11. The suspension according to claim 10, wherein the surfactant is present in an amount up to 5% by weight.

12. The suspension according to claim 9, wherein the weight ratio of surfactant/hydrophilic polymer is between 1/500 and 1/10.

13. The suspension according to claim 2, wherein the weight ratio of surfactant/hydrophilic polymer is between 1/100 and 5/100.

14. The suspension according to claim 9, wherein the surfactant is sodium lauryl sulfate, monooleate, monolaurate, monopalmitate, monostearate or another ester of polyoxyethylene sorbitane, sodium dioctylsulfosuccinate lecithin, stearylic alcohol, cetostearylic alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer, or a mixture of two or more thereof.

15. The suspension according to claim 14, wherein the surfactant is sodium lauryl sulfate.

16. The suspension according to claim 9, wherein the fenofibrate and surfactant are co-micronized.

17. A suspension of micronized having a size less than 20 .mu.m in a solution of at least one hydrophilic polymer and at least one surfactant, wherein the fenofibrate is present in an amount of from 1 to 40% by weight, the hydrophilic polymer is present in an amount from 5 to 40% by weight, and the surfactant is present in an amount up to 10% by weight; and wherein the hydrophilic polymer is a polyvinyl pyrrolidone, a poly(vinyl alcohol), a hydroxypropylcellulose, a hydroxymethylcellulose, a hydroxypropylmethylcellulose, a gelatin, or a mixture of two or more thereof.

18. The suspension according to claim 7, wherein the fenofibrate has a size less than 10 .mu.m.

19. The suspension according to claim 7, wherein the hydrophilic polymer is polyvinylpyrrolidone.

20. The suspension according to claim 7, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/10 and 4/1.

21. The suspension according to claim 19, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/2 and 2/1.

22. The suspension according to claim 17, wherein the weight ratio of surfactant/hydrophilic polymer is between 1/500 and 1/10.

23. The suspension according to claim 22, wherein the weight ratio of surfactant/hydrophilic polymer is between 1/100 and 5/100.

24. The suspension according to claim 17, wherein the surfactant is sodium lauryl sulfate.

25. A suspension of micronized fenofibrate having a size less than 20 .mu.m in a solution of polyvinylpyrrolidone and a surfactant, wherein the fenofibrate is present in an amount from 1 to 40% by weight, the hydrophilic polymer is present in an amount from 5 to 40% by weight and the surfactant is present in an amount up to 10% by weight.

26. The suspension according to claim 25, the fenofibrate has a size less than 10 .mu.m.

27. The suspension according to claim 25, wherein the fenofibrate is present in an from 10 to 25% by weight.

28. The suspension according to claim 25, wherein the hydrophilic polymer is present in an amount from 10 to 25% by weight.

29. The suspension according to claim 25, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/10 and 4/1.

30. The suspension according to claim 29, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/2 and 2/1.

31. The suspension according to claim 25, wherein the surfactant is present in an amount up to 5% by weight.

32. The suspension according to claim 25, wherein the weight ratio of surfactant/hydrophilic polymer is between 1/500 and 1/10.

33. The suspension according to claim 32, wherein the weight ratio of surfactant hydrophilic polymer is between 1/100 and 5/100.

34. The suspension according to claim 1, wherein the surfactant is sodium lauryl sulfate.

35. The suspension of claim 1, wherein the at least one hydrophilic polymer is a mixture of hydrophilic polymers.

36. The suspension of claim 17, wherein the at least one hydrophilic polymer is a mixture of hydrophilic polymers.

37. The suspension of claim 25, wherein the at least one hydrophilic polymer is a mixture of hydrophilic polymers.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Baxter
Fish and Richardson
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Harvard Business School
Covington
Argus Health
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot